Erratum to: CDR132L improves systolic and diastolic function in a large animal model of chronic heart failure

Abstract

.. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. . ticagrelOr Interaction in PatientS with Unstable Angina PectorIS—the METAMORPHOSIS Trial. Thromb Haemost 2018;118:2126–2133. 35. Holm M, Tornvall P, Henareh L, Jensen U, Golster N, Alstrom P, Santos-Pardo I, Witt N, Fedchenko N, Venetsanos D, Beck O, van der Linden J. The MOVEMENT trial. J Am Heart Assoc 2019;8:e010152. 36. Franchi F, Rollini F, Park Y, Hu J, Kureti M, Rivas Rios J, Faz G, Yaranov D, Been L, Pineda AM, Suryadevara S, Soffer D, Zenni MM, Bass TA, Angiolillo DJ. Effects of the peripheral opioid receptor antagonist methylnaltrexone on the PK and PD profiles of ticagrelor in patients with coronary artery disease treated with morphine. JACC Cardiovasc Interv 2019; 12:1538–1549. 37. Storey RF. Antiplatelet therapy. Cangrelor succeeds, at last, in PCI. Nat Rev Cardiol 2013;10:302–304. 38. Storey RF, Sinha A. Cangrelor for the management and prevention of arterial thrombosis. Expert Rev Cardiovasc Ther 2016;14:991–999. 39. Storey RF, Gurbel PA, ten Berg J, Bernaud C, Dangas GD, Frenoux J-M, Gorog DA, Hmissi A, Kunadian V, James SK, Tanguay J-F, Tran H, Trenk D, Ufer M, Van der Harst P, Van’t Hof AWJ, Angiolillo DJ. Pharmacodynamics, pharmacokinetics, and safety of single-dose subcutaneous administration of selatogrel, a novel P2Y12 receptor antagonist, in patients with chronic coronary syndromes. Eur Heart J 2020;41:3132–3140. 40. Alexopoulos D, Barampoutis N, Gkizas V, Vogiatzi C, Tsigkas G, Koutsogiannis N, Davlouros P, Hahalis G, Nylander S, Parodi G, Xanthopoulou I. Crushed versus integral tablets of ticagrelor in ST-segment elevation myocardial infarction patients: a randomized pharmacokinetic/pharmacodynamic study. Clin Pharma cokinet 2016;55:359–367. 41. Venetsanos D, Sederholm Lawesson S, Swahn E, Alfredsson J. Chewed ticagrelor tablets provide faster platelet inhibition compared to integral tablets The inhibition of platelet aggregation after administration of three different ticagrelor formulations (IPAAD-Tica) study, a randomised controlled trial. Thromb Res 2017; 149:88–94. 42. Parodi G, Xanthopoulou I, Bellandi B, Gkizas V, Valenti R, Karanikas S, Migliorini A, Angelidis C, Abbate R, Patsilinakos S, Baldereschi GJ, Marcucci R, Gensini GF, Antoniucci D, Alexopoulos D. Ticagrelor crushed tablets administration in STEMI patients; the MOJITO study. J Am Coll Cardiol 2015;65:511–512. 43. Teng R, Hammarberg M, Carlson GF, Bokelund-Singh S, Ruderfelt T, Blychert E. Pharmacokinetic profiles of ticagrelor orodispersible tablets in healthy Western and Japanese subjects. Clin Drug Investig 2017;37:1035–1045. 44. Parodi G, Talanas G, Mura E, Canonico ME, Siciliano R, Guarino S, Marini A, Dossi F, Franca P, Raccis M, Saba PS, Sanna GD. Orodispersible ticagrelor in acute coronary syndromes: the TASTER study. J Am Coll Cardiol 2021;78: 292–294. 45. Ko Y-G, Suh J-W, Kim BH, Lee CJ, Kim J-S, Choi D, Hong M-K, Seo M-K, Youn T-J, Chae I-H, Choi DJ, Jang Y. Comparison of 2 point-of-care platelet function tests, VerifyNow Assay and Multiple Electrode Platelet Aggregometry, for predicting early clinical outcomes in patients undergoing percutaneous coronary intervention. Am Heart J 2011;161:383–390. 46. Lordkipanidze M, Pharand C, Nguyen TA, Schampaert E, Palisaitis DA, Diodati JG. Comparison of four tests to assess inhibition of platelet function by clopidogrel in stable coronary artery disease patients. Eur Heart J 2008;29: 2877–2885. 4036 H. Fernando et al.